Abstract
Individual tolerance to single or widely spaced doses of methotrexate was explored in 49 patients with advanced cancer with normal serum creatinine and/or blood urea nitrogen. Methotrexate was given as an intravenous infusion over 1 hour at initial doses of 80-120 mg./m2 body surface area. The doses were increased by 50% increments every 2 weeks until moderate toxicity occurred, arbitrarily defined as leukopenia <5000/mm.3, and/or thrombocytopenia <100,000/mm.3, and/or the appearance of oral mucous or intestinal toxicity.
The individual dose required to produce initial evidence of toxicity varied by a factor of 18 between 50 and 900 mg./m2. Starting doses above 80 mg./m2 were potentially hazardous. Dose limiting toxicity consisted of leukopenia with or without stomatitis in 81% of the patients, and stomatitis without leukopenia, in 19%. Thrombocytopenia was seen in 19% of the patients, but was never a dose limiting factor alone. Leukopenia always preceded thrombocytopenia. The nadir for haematologic toxicity varied considerably between day 5-15 and 9-14 for leukocytes and platelets, respectively, while oral ulcerations, when they occurred, consistently began between days 3-6 after drug administration. Other toxic manifestations included dermatologic changes in 8 patients, hepatic dysfunction in 7, conjunctivitis in 7, nausea and vomiting in 6, alopecia in 4, and diarrhea in 3 patients.
The only factor which predicted toxicity was the patient's age. Drug tolerance was independent of previous chemotherapy or radiotherapy, weight loss, serum albumin or pretreatment serum folic acid levels.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Hansen, H., Selawry, O., Holland, J. et al. The Variability of Individual Tolerance to Methotrexate in Cancer Patients. Br J Cancer 25, 298–305 (1971). https://doi.org/10.1038/bjc.1971.38
Issue Date:
DOI: https://doi.org/10.1038/bjc.1971.38
This article is cited by
-
Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome
Indian Journal of Hematology and Blood Transfusion (2022)
-
Herpes simplex virus and oral mucositis in children with cancer
Supportive Care in Cancer (1994)
-
The effect of timing of a single injection on the toxicity of methotrexate in the rat
Cancer Chemotherapy and Pharmacology (1982)
-
Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate
Cancer Chemotherapy and Pharmacology (1981)